


5



- in presence of a suitable solvent and reducing agent to form a compound of formula (I), wherein
 10 all substitutions are as defined in claim 1,
 (b) optionally converting the compound of formula (I) to their pharmaceutically acceptable salts.

4. A pharmaceutical composition comprising a compound according to any of claims 1 to 2 and
 pharmaceutically acceptable excipients.
 15 5. The pharmaceutical composition according to claim 4, for the treatment of clinical conditions
 mediated through H₃ receptor such as cognitive deficits in schizophrenia, narcolepsy, obesity,
 attention deficit hyperactivity disorder, pain or alzheimer's disease.

- 20 ~~6. A method of treating cognitive deficits in schizophrenia, narcolepsy, obesity, attention deficit
 hyperactivity disorder, pain or alzheimer's disease, comprising administering to a patient in need
 thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according
 to any one of claims 1 to 2.~~

- ⁶
 25 ~~7.~~ Use of a compound according to any one of the claims 1 to 2 in the manufacture of
 medicament for the treatment of diseases related to Histamine H₃ receptors.

- ¹ ⁶
 30 ~~8.~~ The use of compound according to the claim ~~7~~, for the treatment of clinical conditions such as
 cognitive deficits in schizophrenia, narcolepsy, obesity, attention deficit hyperactivity disorder,
 pain or alzheimer's disease.

35